The approval follows the positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) in October 2022
The funds raised through the issue will be utilised to meet the working capital requirements to fund the company's expansion plans, entering new geographies and for general corporate purposes
The proceeds of the issue has been/will be reinvested in the company and to meet its own business requirements.
Shandong Meditech Medical Technology is a manufacturer of onsite oxygen solutions for the healthcare market.
The IPO is a complete OFS by existing shareholder Helix Investment Holdings
Proceeds from the transaction will be reinvested towards the growth, innovation and expansion of Healthium’s advanced surgery, orthopaedics, wound care and post-surgical care portfolio
Natco Chlorantraniliprole (CTPR) Process does not infringe FMC's Indian Patent 298645.
Tambe has been with Biocon since 1997 and has held diverse leadership and operational roles.
Move to increase affordability and accessibility for heart failure patients across the country
Subscribe To Our Newsletter & Stay Updated
